Biomaterial Database

Chronic leg ulcerations associated with livedoid vasculopathy successfully treated with rivaroxaban. 2020

D Miguel, and P Elsner, and S Goetze

Department of Dermatology, Jena University Hospital, Jena, Germany.

UI	MeSH Term	Description	Entries
D007871	Leg Ulcer	Ulceration of the skin and underlying structures of the lower extremity. About 90% of the cases are due to venous insufficiency (VARICOSE ULCER), 5% to arterial disease, and the remaining 5% to other causes.	Leg Ulcers,Ulcer, Leg,Ulcers, Leg
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069552	Rivaroxaban	A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.	5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide,BAY 59-7939,Xarelto,BAY 59 7939,BAY 597939
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D012867	Skin	The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D017445	Skin Diseases, Vascular	Skin diseases affecting or involving the cutaneous blood vessels and generally manifested as inflammation, swelling, erythema, or necrosis in the affected area.	Cutaneous Vasculitis,Vascular Skin Diseases,Cutaneous Vasculitides,Skin Disease, Vascular,Vascular Skin Disease,Vasculitis, Cutaneous
D065427	Factor Xa Inhibitors	Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.	Direct Factor Xa Inhibitor,Direct-Acting Oral Anticoagulant,Direct-Acting Oral Anticoagulants,Factor Xa Inhibitor,Direct Factor Xa Inhibitors,Anticoagulant, Direct-Acting Oral,Anticoagulants, Direct-Acting Oral,Direct Acting Oral Anticoagulant,Direct Acting Oral Anticoagulants,Inhibitor, Factor Xa,Oral Anticoagulant, Direct-Acting,Oral Anticoagulants, Direct-Acting,Xa Inhibitor, Factor